Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event
Recruiting
Observational Study
Hyperlipidemia
Cardio Vascular Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Chinese University of Hong Kong · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the fir…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age \>18
* (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
* (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease
Exclusion Criteria:
* Inability to provide valid consent by the patien…
Contacts